Moderna & United Kingdom

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

United Kingdom: The United Kingdom is providing up to £20 million to contain the Ebola outbreak in the Democratic Republic of the Congo and Uganda, supporting international efforts and frontline health workers.

Moderna: Moderna>>> developed the mRNA-4194 vaccine using its mRNA technology, marking its first venture into cancer prevention, which could significantly expand its market and revenue streams.

United Kingdom: The United Kingdom>>> is the location for the clinical trials of the mRNA-4194 vaccine, with multiple centers participating in the study.

Moderna: Moderna is an immigrant-founded unicorn company that has gone public since 2016.

United Kingdom: The United Kingdom is third in the number of immigrant founders of US billion-dollar companies.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

United Kingdom: The United Kingdom has ruled out temperature checks at its airports for flights from affected regions, indicating a low perceived global risk from the Ebola outbreak, but also highlighting past ineffectiveness of such measures.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

United Kingdom: The United Kingdom>>> is one of multiple nations that have implemented travel restrictions in response to the Ebola outbreak, indicating a global concern.